PCF raises a record $47 million to support research; more than $530 since 1993
100th Young Investigator is announced
Movember raises $7.5 million to support PCF-funded research, including $2.5 million to support a Dream Team
PCF and Stand Up to Cancer announce two Prostate Cancer Dream Teams for research
PCF’s global research enterprise expands with PCF China program
$43.1 million is raised to support PCF-sponsored research
PCF reaches 5 million Facebook community friends
Four new drugs for patients with advanced prostate cancer make their way into the clinic in two years
Safeway raises more than $75 million of 10 years to support PCF research
Safeway campaign raises $9.77 million for PCF, exceeding $58 million in nine years.
More than 64,900 U.S. registrants participated in month-long Movember activities, bringing in more than $2 million to support PCF research programs.
PCF increases awareness and promotes government engagement with Advance on Washington events at 17th Annual Scientific Retreat. PCF mobilizes meetings and spearheads efforts with ZERO, PHEN and the BBHOP and focuses on prostate cancer research and discovery, advocacy, legislation and healthcare disparities.
2010 was the greatest year ever for prostate cancer research with more progress being made in 12 months than in the preceding decade. Among the historic number of milestones that will someday enable us to cure more and overtreat less through personalized treatment:
- The identification of 24 genomic subtypes of prostate cancer, moving one step closer to being able to discern between highly-aggressive and non-life-threatening forms of prostate cancer for better diagnosis and treatment planning.
- Three new drug therapies approved by the FDA for patients: Provenge (sipuleucel-T), the first immunotherapy to stimulate the body’s immune system to fight metastatic prostate cancer, Jevtana (cabazitaxel), an enhanced chemotherapy for patients with advanced prostate cancer, and Xgeva (denusomab), used to prevent bone fractures in men undergoing androgen deprivation therapy.
- 28 new prostate cancer drugs entered Phase I/II clinical trials; eight new drugs, including Abiraterone, MDV3100 and denosumab (for new indication), entered Phase III trials
- PCF-supported scientist, Daniel Haber, MD, PhD speeds the development of liquid biopsies (using microfluidic devices to capture circulating tumor cells) for patients with a $30 million development agreement with Veridex, a division of Johnson and Johnson.
Eighth year of Safeway campaign brings in almost $10 million for PCF.
The third year of Movember raises almost $40 million globally. In the US, the Lance Armstrong Foundation is added as a beneficiary, raising awareness and participants with $1.1 million raised for PCF.
Despite global recession, PCF reports best year ever and reports $400 million in funded research since 1993.
PCF initiates special outreach to the African-American community with a new guide, Straight Talk for African-American Men and Their Families. R&B artist Charlie Wilson becomes a spokesperson and PCF partners with the Black Barbershop Health Outreach Program to increase awareness.
PCF funded early research on two drugs that are making their way through clinical trials and the approval process: Abiraterone and Provenge.
An updated guide about Nutrition, Exercise, and Prostate Cancer is released.
Daniel Haber, MD, PhD, at Massachusetts General Hospital develops a tool to collect and count rare circulating tumor cells (CTCs) using PCF funding. CTCs are a possible biomarker for improved survival rates and could shorten the time required to test new medicines.
Winter Vinecki partners with PCF to create Team Winter and the 11-year-old raises over $150,000 for prostate cancer research.
PCF conducts a comprehensive review of its competitive awards program from 1993 to 2006. Building on the success of these awards, PCF develops a new strategy designed to focus on specific assets in the field of prostate cancer research.
PCF-funded researcher Arul Chinnaiyan, MD, PhD, and colleagues at the University of Michigan discover an “on-switch” for prostate cancer. In addition to new targeted therapies, the discovery may one lead to a simple urine test for detecting aggressive forms of prostate cancer.
Movember comes to the United States and helps raise awareness of prostate cancer by literally changing the face of men’s health with participants growing mustaches in the month of Movember (formerly November).
Dr. Jonathan Simons named new President and CEO of the Prostate Cancer Foundation.
Athletes for a Cure is launched to help athletes increase awareness of prostate cancer and raise money for prostate cancer research.
PCF publishes three new guides for patients and their families Report to the Nation on Prostate Cancer: A Guide for Men and Their Families, Nutrition and Prostate Cancer and Introduction to Prostate Cancer.
Fortune magazine notes that PCF and Mike Milken have “…managed to raise the profile of prostate cancer significantly, increase funding dramatically to fight the disease, spur innovative research, attract new people to the field, get myriad drugs into clinical trials, and dare we say, speed up science.”
The 2004 Noble Prize in Chemistry recipient, Aaron Ciechanover, MD, DSc, is a recipient of multiple PCF research grants, to support his award-winning research of the proteasome, which regulates the abundance of key proteins involved in cell survival.
PCF publishes a prostate cancer guide for healthcare professionals, Report to the Nation on Prostate Cancer. More than 17,000 copies are distributed free of charge.
Millennium Pharmaceuticals gets FDA approval for Velcade, a proteasome inhibitor that was studied with PCF funding in Phase 1 with the help of PCF-funded researcher Christopher Logothetis, MD (M.D. Anderson Cancer Center).
Work by leaders in the PCF Therapy Consortium contributes to the development of taxane-based chemotherapy regimens for advanced prostate cancer. Aventis Pharmaceuticals develops Taxotere for use in prostate cancer.
The Prostate Cancer Foundation unveils its new name, replacing CaP CURE.
With early PCF funding and researcher involvement in clinical trials, AstraZeneca takes Iressa, an EGF receptor tyrosine kinase inhibitor, into clinical development for advanced prostate cancer.
Since 1993, total government funding of prostate cancer research has grown by a factor of 20 to $500 million.
Harvard researcher Anthony D’Amico, MD, PhD, publishes a study with PCF support showing that a doubling of a man’s PSA score in three months is a strong statistical predictor of death from prostate cancer.
Partnering with Arnold Palmer, PCF launches new golf program: Arnie’s Army Battles Prostate Cancer.
The FDA approves Novartis’ new drug, Zometa, for treating prostate cancer and other solid tumors. Early research funded by the PCF is a crucial contribution.
Safeway, Inc. launches a new customer and employee donation campaign to benefit prostate cancer, raising $750,000.
U.S. News & World Report: “[The PCF’s] work is making a difference and has led to 70 human clinical trials.”
PCF-funded researchers at Johns Hopkins announce a vaccine to strengthen the immune system against prostate cancer.
Molecular and cell biologist James Allison, PhD (University of California, Berkeley), uses PCF funding to study the CTLA-4 molecule. Monoclonal antibodies like CTLA-4 help new cancer vaccines work more effectively.
PCF establishes Young Investigator Awards, providing six, three-year $150,000 research grants.
THE MARCH, with heavy PCF involvement, draws 500,000 marchers to 200 cities and Washington’s National Mall.
With seed funds from PCF, Neal Rosen, MD, PhD, demonstrates that geldanamycin destroys molecules that cause prostate cancer growth.
PCF publishes the first Nutrition & Prostate Cancer paper.
The first PCF/Major League Baseball Home Run Challenge (HRC) to raise funds for research garners widespread print and broadcast coverage in cities across the country.
The PCF Therapy Consortium is launched to coordinate clinical trials and related research at leading U.S. cancer centers to enroll patients in trials faster and accelerate the approval of new medicines
Following more than 100 Congressional visits by PCF board members, led by Intel Chairman Andy Grove, Congress approves a Prostate Cancer Research Program in the Department of Defense with an initial appropriation of $45 million.
PCF-funded Charles Sawyers, MD (UCLA) discovers new pathways of cancer development in a tumor suppressor molecule.
PCF researcher John Reed, MD, PhD (Burnham Institute, San Diego), develops benchmark understanding of apoptosis (cell death), which has led to potential new treatments for all forms of cancer.
PCF organizes the National Cancer Summit in Washington.
PCF-funded researchers hold a Tissue Bank Summit to establish protocols for harvesting prostate-cancer tissue.
Joel Nelson, MD, and Michael Carducci, MD, use PCF funding to discover that a cardiovascular disease (Atrasentan) may be helpful for prostate cancer patients.
Dr. Jonathan Simons, at Johns Hopkins University, is funded by PCF. He will develop GVAX, a promising anti-prostate cancer vaccine.
PCF-funded researcher John Kurhanewicz, PhD (University of California, San Francisco), develops a new imaging system that locates metastasized disease and measures its aggressiveness.
Nearly 100 scientists and physicians attend the PCF’s first annual Scientific Retreat in Santa Barbara.
Neil Bander, MD, produces monoclonal antibodies to PSMA (Prostate Specific Membrane Antigen) that bind to living cells.
The Prostate Cancer Foundation is founded (originally called CaP CURE: Association for the Cure of Cancer of the Prostate).
PCF establishes its groundbreaking awards process, which limits applications to five pages and funds approved research applications within 90 days.
The first competitive research award winners receive $4.5 million in grants.
The first of five grants are made to Judah Folkman, MD (Harvard Medical School) to continue his work in the area of anti-angiogenesis. Folkman’s work will influence not only prostate cancer research, but nearly every branch of oncology.